Anti-CD38 antibody-drug conjugate
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Anti-CD38 antibody-drug conjugate, covering 2023-04-12 to 2025-08-15. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]